REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the safety and activity of combined hormonal
chemoimmunotherapy in a single-arm phase II trial of REGN2810, androgen deprivation therapy
(ADT), and docetaxel in patients with newly metastatic, hormone-sensitive prostate cancer
(mHSPC), using a primary endpoint of undetectable prostate-specific antigen (PSA) at 6
months, defined from start of combination therapy (week 10) until 6 months (week 37).